-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
On November 22, Connoa announced that its wholly-owned subsidiary, Connoa Biomedical Technology (Chengdu) Co.
CM326 is a class 1 innovative drug with a new mechanism of action developed by Chengdu Connoa, which targets thymic stromal lymphopoietin (TSLP)
Pre-clinical studies have shown that CM326 has good safety and excellent efficacy.
According to the agreement, Connoa will grant the exclusive license of CSPC CM326 to develop and commercialize the product in China (excluding Hong Kong, Macau and Taiwan) and become the holder of the marketing license
Public information shows that this is another collaboration between Connoa and CSPC after signing an exclusive license for CM310
According to the press release, CM326 is one of Connoa’s key products and has the potential to form complementary synergies with CM310 in this field
Reference materials:
[1] Information Express | Connoa authorized CSPC CM326 to develop and commercialize the exclusive license for moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
